Chemoradiotherapy in patients with anal cancer: Impact of length of unplanned treatment interruption on outcome
The aim of this retrospective analysis was to evaluate feasibility and effectiveness of definitive chemoradiotherapy without split-course technique in anal cancer patients. From 1993 to 2003, 81 patients were treated; 13 were excluded due to various chemotherapeutic regimes, thus 68 patients were an...
Gespeichert in:
Veröffentlicht in: | Acta oncologica 2006, Vol.45 (6), p.728-735 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 735 |
---|---|
container_issue | 6 |
container_start_page | 728 |
container_title | Acta oncologica |
container_volume | 45 |
creator | Meyer, Andreas Meier Zu Eissen, Jürgen Karstens, Johann H. Bremer, Michael |
description | The aim of this retrospective analysis was to evaluate feasibility and effectiveness of definitive chemoradiotherapy without split-course technique in anal cancer patients. From 1993 to 2003, 81 patients were treated; 13 were excluded due to various chemotherapeutic regimes, thus 68 patients were analysed. In case of acute grade 3 toxicities, treatment was halted until improvement or resolution independent of dose. Short interruption was defined as completing treatment without exceeding eight cumulative treatment days beyond scheduled plan, other patients were considered to have had prolonged interruption. Median follow-up was 46 months. Median overall treatment time was 53 days corresponding to an interruption of eight cumulative treatment days. Thirty-five patients (51%) had treatment interruption of ≤8 days. No acute grade 4 toxicities were observed; one fatality occurred during treatment due to ileus-like symptoms according to acute grade 5 toxicity. Comparing patients with short vs. prolonged interruption 5-year actuarial rates for local control were 85% vs. 81% (p = 0.605) and for colostomy-free survival 85% vs. 87% (p = 0.762), respectively. Chemoradiotherapy with short individualised treatment interruptions seems to be feasible with acceptable acute or late toxicities. Treatment is highly effective in terms of local control and colostomy-free survival. |
doi_str_mv | 10.1080/02841860600726729 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_02841860600726729</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16938816</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-44c1796b7386e611829cf53057df8ac9a61b1f1b35895b70028da07eb74c9ad53</originalsourceid><addsrcrecordid>eNp9kN1KwzAUx4Mobk4fwBvJC1STfiSpXsmYOhh4o7C7cpqe2o42KWmK7O3N2MALQThwDvw_4PwIueXsnjPFHlisUq4EE4zJWMg4PyNzLjIexbHYnpP5QY-CYTsjV-O4Y4zFicwuyYyLPFGKizmxywZ766BqrW_QwbCnraED-BaNH-l36xsKBjqqwWh0j3TdD6A9tTXt0HwFNVyTGTowBivqHYLvQzS0eHRuGnxrDT3M5LXt8Zpc1NCNeHPaC_L5svpYvkWb99f18nkT6SRPfZSmmstclDJRAgXnKs51nSUsk1WtQOcgeMlrXiaZyrNShsdUBUxiKdMgVlmyIPzYq50dR4d1Mbi2B7cvOCsO8Io_8ELm7pgZprLH6jdxohUMT0dDa2rremgQOt9ocFjs7OQCpvGf-h_8VX5P</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chemoradiotherapy in patients with anal cancer: Impact of length of unplanned treatment interruption on outcome</title><source>MEDLINE</source><source>Access via Taylor & Francis</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Meyer, Andreas ; Meier Zu Eissen, Jürgen ; Karstens, Johann H. ; Bremer, Michael</creator><creatorcontrib>Meyer, Andreas ; Meier Zu Eissen, Jürgen ; Karstens, Johann H. ; Bremer, Michael</creatorcontrib><description>The aim of this retrospective analysis was to evaluate feasibility and effectiveness of definitive chemoradiotherapy without split-course technique in anal cancer patients. From 1993 to 2003, 81 patients were treated; 13 were excluded due to various chemotherapeutic regimes, thus 68 patients were analysed. In case of acute grade 3 toxicities, treatment was halted until improvement or resolution independent of dose. Short interruption was defined as completing treatment without exceeding eight cumulative treatment days beyond scheduled plan, other patients were considered to have had prolonged interruption. Median follow-up was 46 months. Median overall treatment time was 53 days corresponding to an interruption of eight cumulative treatment days. Thirty-five patients (51%) had treatment interruption of ≤8 days. No acute grade 4 toxicities were observed; one fatality occurred during treatment due to ileus-like symptoms according to acute grade 5 toxicity. Comparing patients with short vs. prolonged interruption 5-year actuarial rates for local control were 85% vs. 81% (p = 0.605) and for colostomy-free survival 85% vs. 87% (p = 0.762), respectively. Chemoradiotherapy with short individualised treatment interruptions seems to be feasible with acceptable acute or late toxicities. Treatment is highly effective in terms of local control and colostomy-free survival.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.1080/02841860600726729</identifier><identifier>PMID: 16938816</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Adult ; Aged ; Analysis of Variance ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Anus Neoplasms - drug therapy ; Anus Neoplasms - radiotherapy ; Cyclophosphamide - therapeutic use ; Dose Fractionation ; Female ; Fluorouracil - therapeutic use ; Humans ; Male ; Melphalan - therapeutic use ; Middle Aged ; Radiotherapy Dosage ; Retrospective Studies ; Semustine - therapeutic use ; Time Factors ; Treatment Outcome</subject><ispartof>Acta oncologica, 2006, Vol.45 (6), p.728-735</ispartof><rights>2006 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-44c1796b7386e611829cf53057df8ac9a61b1f1b35895b70028da07eb74c9ad53</citedby><cites>FETCH-LOGICAL-c394t-44c1796b7386e611829cf53057df8ac9a61b1f1b35895b70028da07eb74c9ad53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/02841860600726729$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/02841860600726729$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,61221,61402</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16938816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meyer, Andreas</creatorcontrib><creatorcontrib>Meier Zu Eissen, Jürgen</creatorcontrib><creatorcontrib>Karstens, Johann H.</creatorcontrib><creatorcontrib>Bremer, Michael</creatorcontrib><title>Chemoradiotherapy in patients with anal cancer: Impact of length of unplanned treatment interruption on outcome</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>The aim of this retrospective analysis was to evaluate feasibility and effectiveness of definitive chemoradiotherapy without split-course technique in anal cancer patients. From 1993 to 2003, 81 patients were treated; 13 were excluded due to various chemotherapeutic regimes, thus 68 patients were analysed. In case of acute grade 3 toxicities, treatment was halted until improvement or resolution independent of dose. Short interruption was defined as completing treatment without exceeding eight cumulative treatment days beyond scheduled plan, other patients were considered to have had prolonged interruption. Median follow-up was 46 months. Median overall treatment time was 53 days corresponding to an interruption of eight cumulative treatment days. Thirty-five patients (51%) had treatment interruption of ≤8 days. No acute grade 4 toxicities were observed; one fatality occurred during treatment due to ileus-like symptoms according to acute grade 5 toxicity. Comparing patients with short vs. prolonged interruption 5-year actuarial rates for local control were 85% vs. 81% (p = 0.605) and for colostomy-free survival 85% vs. 87% (p = 0.762), respectively. Chemoradiotherapy with short individualised treatment interruptions seems to be feasible with acceptable acute or late toxicities. Treatment is highly effective in terms of local control and colostomy-free survival.</description><subject>Adult</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Anus Neoplasms - drug therapy</subject><subject>Anus Neoplasms - radiotherapy</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Dose Fractionation</subject><subject>Female</subject><subject>Fluorouracil - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Melphalan - therapeutic use</subject><subject>Middle Aged</subject><subject>Radiotherapy Dosage</subject><subject>Retrospective Studies</subject><subject>Semustine - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kN1KwzAUx4Mobk4fwBvJC1STfiSpXsmYOhh4o7C7cpqe2o42KWmK7O3N2MALQThwDvw_4PwIueXsnjPFHlisUq4EE4zJWMg4PyNzLjIexbHYnpP5QY-CYTsjV-O4Y4zFicwuyYyLPFGKizmxywZ766BqrW_QwbCnraED-BaNH-l36xsKBjqqwWh0j3TdD6A9tTXt0HwFNVyTGTowBivqHYLvQzS0eHRuGnxrDT3M5LXt8Zpc1NCNeHPaC_L5svpYvkWb99f18nkT6SRPfZSmmstclDJRAgXnKs51nSUsk1WtQOcgeMlrXiaZyrNShsdUBUxiKdMgVlmyIPzYq50dR4d1Mbi2B7cvOCsO8Io_8ELm7pgZprLH6jdxohUMT0dDa2rremgQOt9ocFjs7OQCpvGf-h_8VX5P</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>Meyer, Andreas</creator><creator>Meier Zu Eissen, Jürgen</creator><creator>Karstens, Johann H.</creator><creator>Bremer, Michael</creator><general>Informa UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2006</creationdate><title>Chemoradiotherapy in patients with anal cancer: Impact of length of unplanned treatment interruption on outcome</title><author>Meyer, Andreas ; Meier Zu Eissen, Jürgen ; Karstens, Johann H. ; Bremer, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-44c1796b7386e611829cf53057df8ac9a61b1f1b35895b70028da07eb74c9ad53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Anus Neoplasms - drug therapy</topic><topic>Anus Neoplasms - radiotherapy</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Dose Fractionation</topic><topic>Female</topic><topic>Fluorouracil - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Melphalan - therapeutic use</topic><topic>Middle Aged</topic><topic>Radiotherapy Dosage</topic><topic>Retrospective Studies</topic><topic>Semustine - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meyer, Andreas</creatorcontrib><creatorcontrib>Meier Zu Eissen, Jürgen</creatorcontrib><creatorcontrib>Karstens, Johann H.</creatorcontrib><creatorcontrib>Bremer, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meyer, Andreas</au><au>Meier Zu Eissen, Jürgen</au><au>Karstens, Johann H.</au><au>Bremer, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemoradiotherapy in patients with anal cancer: Impact of length of unplanned treatment interruption on outcome</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>2006</date><risdate>2006</risdate><volume>45</volume><issue>6</issue><spage>728</spage><epage>735</epage><pages>728-735</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><abstract>The aim of this retrospective analysis was to evaluate feasibility and effectiveness of definitive chemoradiotherapy without split-course technique in anal cancer patients. From 1993 to 2003, 81 patients were treated; 13 were excluded due to various chemotherapeutic regimes, thus 68 patients were analysed. In case of acute grade 3 toxicities, treatment was halted until improvement or resolution independent of dose. Short interruption was defined as completing treatment without exceeding eight cumulative treatment days beyond scheduled plan, other patients were considered to have had prolonged interruption. Median follow-up was 46 months. Median overall treatment time was 53 days corresponding to an interruption of eight cumulative treatment days. Thirty-five patients (51%) had treatment interruption of ≤8 days. No acute grade 4 toxicities were observed; one fatality occurred during treatment due to ileus-like symptoms according to acute grade 5 toxicity. Comparing patients with short vs. prolonged interruption 5-year actuarial rates for local control were 85% vs. 81% (p = 0.605) and for colostomy-free survival 85% vs. 87% (p = 0.762), respectively. Chemoradiotherapy with short individualised treatment interruptions seems to be feasible with acceptable acute or late toxicities. Treatment is highly effective in terms of local control and colostomy-free survival.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>16938816</pmid><doi>10.1080/02841860600726729</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0284-186X |
ispartof | Acta oncologica, 2006, Vol.45 (6), p.728-735 |
issn | 0284-186X 1651-226X |
language | eng |
recordid | cdi_crossref_primary_10_1080_02841860600726729 |
source | MEDLINE; Access via Taylor & Francis; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Adult Aged Analysis of Variance Antineoplastic Combined Chemotherapy Protocols - therapeutic use Anus Neoplasms - drug therapy Anus Neoplasms - radiotherapy Cyclophosphamide - therapeutic use Dose Fractionation Female Fluorouracil - therapeutic use Humans Male Melphalan - therapeutic use Middle Aged Radiotherapy Dosage Retrospective Studies Semustine - therapeutic use Time Factors Treatment Outcome |
title | Chemoradiotherapy in patients with anal cancer: Impact of length of unplanned treatment interruption on outcome |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A16%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemoradiotherapy%20in%20patients%20with%20anal%20cancer:%20Impact%20of%20length%20of%20unplanned%20treatment%20interruption%20on%20outcome&rft.jtitle=Acta%20oncologica&rft.au=Meyer,%20Andreas&rft.date=2006&rft.volume=45&rft.issue=6&rft.spage=728&rft.epage=735&rft.pages=728-735&rft.issn=0284-186X&rft.eissn=1651-226X&rft_id=info:doi/10.1080/02841860600726729&rft_dat=%3Cpubmed_cross%3E16938816%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16938816&rfr_iscdi=true |